• Explore /
  • Poster
  • / Effect of Tabernero's prognostic subgroups or development of neutropenia on survival outcomes of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil plus bevacizumab (TASBEV) in real-world practice.

Effect of Tabernero's prognostic subgroups or development of neutropenia on survival outcomes of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil plus bevacizumab (TASBEV) in real-world practice.

Abstract Poster

Authors

null

Nieves P. Martinez-Lago

University Hospital A Coruña, A Coruña, Spain;

Nieves P. Martinez-Lago , Beatriz Alonso de Castro , Cristina Reboredo Rendo , Teresa Calleja , Martín Igor Gómez-Randulfe Rodríguez , Sofia Silva Diaz , Iria Parajó Vázquez , Maria Mateos Salvador , Fernando Busto Fernandez , Begona Grana Suarez , Juan De la camara , Margarita Reboredo Lopez

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 99)

DOI

10.1200/JCO.2023.41.4_suppl.99

Abstract #

99

Poster Bd #

E16

Abstract Disclosures

Similar Posters

First Author: Eiji Shinozaki

First Author: Yoshinori Kagawa

First Author: Julien Taieb

First Author: Joleen M. Hubbard